

Dr Reddy's Labs

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	DRRD IN
Equity Shares (m)	834
M.Cap.(INRb)/(USDb)	964.5 / 11.3
52-Week Range (INR)	1421 / 1020
1, 6, 12 Rel. Per (%)	-2/-9/-11
12M Avg Val (INR M)	2884

Financials & Valuations (INR b)

Y/E MARCH	FY25	FY26E	FY27E
Sales	324.3	347.0	350.1
EBITDA	85.5	89.5	85.8
Adj. PAT	56.1	58.5	54.6
EBITDA Margin (%)	26.4	25.8	24.5
Adj. EPS (INR)	67.3	70.3	65.6
EPS Gr. (%)	6.1	4.4	-6.7
BV/Sh. (INR)	405	470	531
Ratios			
Net D:E	-0.1	-0.3	-0.6
RoE (%)	18.2	16.1	13.1
RoCE (%)	14.7	12.1	10.4
Payout (%)	7.7	7.1	7.6
Valuations			
P/E (x)	17.2	16.5	17.7
EV/EBITDA (x)	11.0	10.1	9.6
Div. Yield (%)	0.4	0.4	0.4
FCF Yield (%)	1.4	3.8	8.2
EV/Sales (x)	2.9	2.6	2.4

Shareholding Pattern (%)

As On	Mar-25	Dec-24	Mar-24
Promoter	26.6	26.6	26.7
DII	25.6	22.9	18.3
FII	37.6	40.2	44.7
Others	10.2	10.2	10.4

FII includes depository receipts

CMP: INR1,156

TP: INR1,220 (+6%)

Neutral

FY25 ends with a modest YoY earnings growth

Work in progress to add growth levers

- Dr Reddy's Labs (DRRD) delivered in-line sales, while a slight miss on EBITDA for 4QFY25. The company posted healthy growth in revenue across the segments, partly aided by the addition of acquired businesses. In addition, pharmaceutical services and active ingredients saw a healthy revival in FY25 performance vs. the muted show in FY23/FY24.
- We broadly retain our earnings estimates for FY25/FY27. We value DRRD at 18x 12M forward earnings to arrive at our TP of INR1,220.
- After three years of a strong 30% earnings CAGR over FY21-24E, the company ended FY25 with a moderate 6% earnings growth. DRRD is implementing a plan to expand product offerings across markets and add/ build capacity to cater to the respective markets. Having said this, the intensified competitive pressures in the base portfolio would keep earnings growth in check.
- Accordingly, we model stable earnings over FY25-27. **Reiterate Neutral.**

Inferior product mix offset by lower opex

- DRRD's 4QFY25 sales rose 20% YoY to INR85b (vs. est. of INR83b).
- The US sales increased 9% YoY to INR36b (~USD416m; 42% of sales), largely due to a rise in volumes of the base business and new launches, partly offset by price erosion. Europe sales surged 2.4x YoY to INR12.7b (15% of sales). India sales rose 16% YoY to INR13b (15% of sales). Emerging markets' sales improved 16% YoY to INR14b (16% of sales).
- Pharmaceutical Services and Active Ingredients (PSAI) segment's revenue grew 16% YoY to INR9.5b (11% of sales).
- Gross margin (GM) contracted 300bp YoY to 55.6%, mainly due to lower margins in the global generics business (down 270bp YoY). This was partly offset by a higher gross margin in the PSAI segment.
- EBITDA margin dipped 80bp YoY to 24% (our est: 26.5%) as lower GM was offset by lower expenses (R&D/SGA down 100bp/110bp YoY as % of sales).
- EBITDA was up 16% YoY to INR20.5b (vs. est. of INR21.9b).
- PAT grew at a higher rate of 26.7% YoY to INR15.4b, supported further by higher other income.
- During FY25, revenue/EBITDA/PAT grew 16%/9%/6% YoY to INR324b/INR85.5b/INR56b.

Highlights from the management commentary

- Management guided a double-digit YoY revenue growth and will maintain the EBITDA margin at FY25 levels in FY26.
- A certain one-time cost hurt gross margin by 80bp for the quarter.
- DRRD launched 7/18 products in NA in 4QFY25/FY25.

Quarterly Performance - IFRS										(INRb)		
Y/E March	FY24				FY25E				FY24E	FY25E	Estimates	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	% Var
Sales	67.4	68.8	72.1	70.8	76.7	80.2	82.3	85.1	279.2	324.3	82.8	2.8
YoY Change (%)	35.2	9.1	6.6	17.4	13.9	16.5	14.1	20.1	15.9	16.2	16.9	
EBITDA	20.5	20.0	20.3	17.7	21.3	22.0	21.7	20.5	78.4	85.5	21.9	-6.4
YoY Change (%)	97.8	10.7	-1.3	34.0	4.0	10.3	7.1	16.1	26.2	9.1	24.0	
Margins (%)	30.3	29.0	28.1	24.9	27.7	27.5	26.4	24.1	28.1	26.4	26.5	
Amortization	3.6	3.8	3.9	3.5	3.8	4.0	4.7	4.6	14.8	17.1	4.9	
EBIT	16.9	16.1	16.4	14.1	17.5	18.1	17.0	16.0	63.5	68.5	17.0	
Other Income	1.1	1.6	2.0	1.7	1.4	2.6	0.5	3.4	6.4	7.8	0.7	
PBT before EO expenses	18.0	17.7	18.4	15.8	18.8	20.7	17.5	19.3	69.9	76.3	17.7	9.0
One-off income/(expense)	0.5	1.4	-0.1	0.2	0.0	-1.5	1.3	0.7	2.0	0.5	0.0	
Profit before Tax	18.5	19.1	18.3	16.0	18.8	19.2	18.7	20.1	71.9	76.8	17.7	13.1
Tax	4.4	4.3	4.5	2.9	4.9	5.8	4.7	4.2	16.2	19.5	4.0	
Rate (%)	24.0	22.7	24.5	18.4	26.0	30.0	25.1	20.8	22.5	25.4	22.6	
PAT	14.0	14.8	13.8	13.1	13.9	13.4	14.0	15.9	55.7	57.2	13.7	15.6
Adjusted PAT	13.7	13.3	13.8	12.1	13.9	13.6	13.2	15.4	52.8	56.1	11.8	30.0
YoY Change (%)	66.6	16.5	5.1	50.1	2.0	2.4	-4.3	26.7	29.6	6.1	-2.5	
Margins (%)	20.3	19.3	19.1	17.1	18.1	17.0	16.0	18.1	18.9	17.3	14.3	
EPS	16.4	15.9	16.5	14.5	16.7	16.3	15.8	18.4	63.4	67.3	14.3	10.7

Key performance Indicators (Consolidated)										(INRb)	
Y/E March	FY24				FY25				FY24	FY25	FY25
	INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
North America	32.0	31.7	33.5	32.6	38.5	37.3	33.8	35.6	129.9	144.1	34.5
YoY Change (%)	79.5	13.2	9.6	28.8	20.3	17.6	1.0	9.1	27.7	10.9	5.8
Europe	5.1	5.3	5.0	5.2	5.3	5.8	12.1	12.8	20.5	35.0	11.9
YoY Change (%)	22.5	25.9	15.5	5.0	3.8	9.2	143.4	144.8	16.5	70.6	127.8
India	11.5	11.9	11.8	11.3	13.3	14.0	13.5	13.0	46.4	53.1	12.4
YoY Change (%)	3.9	3.1	4.7	10.5	15.4	17.8	14.1	15.8	5.4	14.5	10.5
Russia & Others CIS	7.6	8.0	8.2	7.2	7.4	9.0	9.4	8.9	30.9	35.7	9.9
YoY Change (%)	49.8	-1.2	-9.9	-4.0	-2.6	12.5	14.6	23.6	3.8	15.4	37.0
Others	4.0	4.2	4.6	4.9	3.7	5.6	5.0	5.1	17.7	19.7	5.4
YoY Change (%)	-0.1	2.2	15.9	34.3	-5.3	32.1	7.0	3.9	12.8	10.9	10.0
PSAI	6.7	7.0	7.8	8.2	7.7	8.4	8.2	9.6	29.8	32.5	8.2
YoY Change (%)	-5.4	9.3	1.0	5.5	14.1	19.5	4.8	16.4	2.5	8.9	-0.5
Cost Break-up											
COGS (% of Sales)	41.3	41.3	41.5	41.4	39.6	40.4	42.0	44.4	41.4	40.8	41.1
SG&A (% of Sales)	21.0	21.7	22.7	23.9	24.6	23.0	23.6	22.9	22.3	23.7	23.6
R&D Expenses(% of Sales)	7.4	7.9	7.7	9.7	8.1	9.1	8.1	8.5	8.2	8.5	8.8
Gross Margin (%)	58.7	58.7	58.5	58.6	60.4	59.6	58.0	55.6	58.6	59.2	58.9
EBITDA Margin (%)	30.3	29.0	28.1	24.9	27.7	27.5	26.4	24.1	28.1	27.0	26.5
EBIT Margin (%)	25.0	23.4	22.7	19.9	22.8	22.5	20.7	18.8	22.8	21.6	20.6



Management call highlights

- DRRD has partnered with Shanghai Henlius Biotech to commercialize HLX15 (daratumumab biosimilar) in the US and Europe
- DRRD received Biologics License Application (BLA) acceptance for AVT03 (denosumab biosimilar) developed by partner, Alvotech, for the US market
- DRRD completed the divestment of our manufacturing facility in Shreveport, Louisiana, US.
- DRRD participated in India's 'Jan Aushadi' program with one of our products to provide accessible generic medicines to the public.
- DRRD expects SGA/R&D expenses in FY26 to be similar to those in FY25 as a % of sales.
- The ETR for FY25 was higher due to the reversal of previously recognized deferred tax assets related to land indexation and recognition of previously unrecognized deferred tax assets on operating tax losses. Management guided the ETR to be at similar levels in FY26.

Key exhibits

Exhibit 1: In CC terms, NA sales rose ~5.8% YoY in 4QFY25




Exhibit 2: DF sales grew 15.8% YoY in 4QFY25




Exhibit 3: Gross profit increased 13.9% YoY




Exhibit 4: EBITDA increased 16% YoY





Exhibit 5: R&D expenses as a proportion of sales at 8.5% in 4QFY25



Expect earnings to be steady over the next two years

Peptides/biosimilars to enhance offerings in a regulated market

- In FY25, NA sales grew 9% YoY to USD1.7b; its new launches gained market share in select products, outweighing price erosion in certain products.
- DRRD launched 18 new products and filed 10 ANDAs in FY25.
- There are 76 ANDAs and 3 NDAs under the 505(b)(2) route awaiting approval. Of these ANDAs, 44 are Para IVs, and 20 have the potential to secure the 'First to File' status.
- DRRD has invested considerably in product development and manufacturing capacity in the peptide category.
- Further, DRRD is building a biosimilar pipeline through in-house development as well as partnered products for regulated markets.
- Over FY25-27, we expect US sales to decline 8% to ~INR123b (USD1.5b). While the pipeline continues to remain rich, competition in products such as g-Revlimid would keep growth prospects under check.

Vaccine-driven growth in the India segment in FY25

- In FY25, India delivered a growth of 15.8% YoY to INR54b. In addition to new launches and steady execution in the base portfolio, the vaccine portfolio has been strengthening its growth trajectory in the domestic market.
- Excluding the vaccines business, the India business grew 6% YoY in FY25.
- The company launched 23 products during FY25 and continues to explore some in-licensing and partnership opportunities.
- DRRD is adding a growth driver through supplying medicines under the Jan-Aushadhi program as well.
- We expect a sales CAGR of 14% to reach INR69.8b over FY25-27.

Steady growth momentum in emerging markets

- In FY25, EM sales grew 11% YoY to INR54b, driven by new launches across various countries and a higher volume offtake of existing products.
- Specifically, the Russian business increased 16% YoY in FY25, led by superior execution by DRRD.
- Overall, we expect a sales CAGR of 8% to reach INR62b over FY25-27.

PSAI segment: Volume and new launches to aid growth

- In FY25, the PSAI segment's revenue grew 14% YoY to INR24.3b. DRRD delivered improved performance in the PSAI segment in FY25 after three years of muted performance.
- DRRD introduced new APIs and garnered a higher volume offtake of existing APIs to revive growth in this segment.
- It filed 52 DMFs in 4QFY25, which would provide support for sustainable growth momentum.
- We expect the PSAI business to post an 8% sales CAGR to reach INR39b over FY25-27.

Reiterate Neutral

- We broadly retain our earnings estimates for FY25/FY27. We value DRRD at 18x 12M forward earnings to arrive at our TP of INR1,220.
- After three years of a strong 30% earnings CAGR over FY21-24E, the company ended FY25 with a moderate 6% earnings growth. DRRD is implementing a plan to expand product offerings across markets and add/ build capacity to cater to the respective markets. Having said this, the intensified competitive pressures in the base portfolio would keep earnings growth in check.
- Accordingly, we model stable earnings over FY25-27. **Reiterate Neutral**.

Exhibit 6: P/E chart




Exhibit 7: EV/EBITDA chart



Source: MOFSL, Company, Bloomberg

Source: MOFSL, Company, Bloomberg

Story in charts

Exhibit 8: Expect sales CAGR of ~3.9% over FY25-27




Exhibit 9: NA sales to decline 8% over FY25-27




Exhibit 10: DF sales to exhibit 14% CAGR over FY25-27




Exhibit 11: PSAI to post 8% sales CAGR over FY25-27




Exhibit 12: EBITDA margin to contract 250bp over FY25-27




Exhibit 13: Competition in the base portfolio to keep EBITDA in check




Exhibit 14: R&D expenses to settle at ~8% of sales by FY27





Exhibit 15: EPS to be stable over FY25-27



Source: Company, MOFSL

Source: Company, MOFSL

Financials and valuations

Income Statement										(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	
Net Sales	1,52,051	1,67,400	1,89,722	2,12,227	2,40,936	2,79,164	3,24,269	3,46,993	3,50,071	
Change (%)	7.1	10.1	13.3	11.9	13.5	15.9	16.2	7.0	0.9	
Total Expenditure	1,22,938	1,32,058	1,45,038	1,67,306	1,78,813	2,00,784	2,38,731	2,57,469	2,64,304	
EBITDA	29,113	35,342	44,684	44,921	62,123	78,380	85,538	89,524	85,768	
Change (%)	27.2	21.4	26.4	0.5	38.3	26.2	9.1	4.7	-4.2	
Margin (%)	19.1	21.1	23.6	21.2	25.8	28.1	26.4	25.8	24.5	
Depreciation & Amort.	11,980	12,472	12,798	11,825	12,663	14,847	17,064	18,044	18,204	
Net Interest Exp	1,163	983	-1,653	-2,119	-2,853	-3,494	-4,724	-6,197	-4,648	
One-off (Gains)/Losses	-1,800	7,718	7,700	6,381	-5,445	-1,981	1,491	0	0	
PBT before EO Expense	22,443	25,749	35,001	38,679	53,943	69,889	76,275	78,578	73,312	
Change (%)	56.5	14.7	35.9	10.5	39.5	29.6	9.1	3.0	-6.7	
PBT after EO Expense	22,443	18,033	27,298	32,298	59,388	71,870	74,784	78,578	73,312	
Tax	3,648	-1,466	9,175	8,730	15,300	16,186	19,538	20,037	18,695	
Tax Rate (%)	16.3	-8.1	33.6	27.0	25.8	22.5	26.1	25.5	25.5	
Reported PAT	18,795	19,499	18,123	23,568	44,088	55,684	54,545	58,541	54,618	
Adjusted Net Profit	17,459	21,807	23,834	29,265	40,775	52,827	56,060	58,541	54,618	
Change (%)	62.6	24.9	9.3	22.8	39.3	29.6	6.1	4.4	-6.7	
Margin (%)	11.5	13.0	12.6	13.8	16.9	18.9	17.3	16.9	15.6	

E: MOFSL Estimates

Balance Sheet										(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	
Equity Share Capital	830	830	830	832	833	833	833	833	833	
Reserves	1,39,406	1,55,158	1,75,587	1,89,695	2,30,158	279,717	336,333	390,695	441,135	
Net Worth	1,40,236	1,55,988	1,76,417	1,90,527	2,30,991	2,80,550	3,37,166	3,91,528	4,41,968	
Loans	34,125	17,836	29,444	33,845	13,472	20,020	46,766	45,766	44,766	
Deferred Liabilities/Tax	-3,844	-12,179	-10,397	-12,721	-6,363	-9,865	-4,400	-4,400	-4,400	
Capital Employed	1,70,517	1,61,645	1,95,464	2,11,651	2,38,100	2,90,705	3,79,532	4,32,894	4,82,334	
Gross Block	1,15,385	1,26,148	1,43,664	1,60,797	1,77,753	2,03,024	2,40,963	2,62,551	2,71,413	
Less: Accum. Deprn.	61,533	74,005	86,803	98,628	1,11,291	1,26,138	1,43,202	1,61,246	1,79,449	
Net Fixed Assets	53,852	52,143	56,861	62,169	66,462	76,886	97,761	1,01,305	91,964	
Investments	30,769	33,264	33,115	38,393	62,180	81,250	59,428	59,428	59,428	
Goodwill/Intangibles	47,393	31,711	40,847	31,664	35,094	41,204	108,613	108,613	108,613	
Curr. Assets	88,325	1,02,936	1,24,659	1,51,647	1,50,922	1,77,404	2,08,679	2,58,055	3,15,869	
Inventory	33,579	35,067	45,412	50,884	48,670	63,552	71,085	72,785	68,491	
Account Receivables	39,982	52,015	49,759	66,818	72,485	80,298	90,420	106,276	92,866	
Cash and Bank Balance	2,228	2,053	14,829	14,852	5,779	7,107	14,654	47,207	12,2448	
Others	12,536	13,801	14,659	19,093	23,988	26,447	32,520	31,786	32,063	
Curr. Liability & Prov.	49,822	58,409	60,018	72,222	76,558	86,039	94,949	94,506	93,539	
Account Payables	13,671	15,248	18,109	25,572	26,444	30,919	35,523	35,028	31,538	
Other Current Liabilities	36,151	43,161	41,909	46,650	50,114	55,120	59,426	59,478	62,001	
Net Current Assets	38,503	44,527	64,641	79,425	74,364	91,365	1,13,730	1,63,549	2,22,330	
Appl. of Funds	1,70,517	1,61,645	1,95,464	2,11,651	2,38,100	2,90,705	3,79,532	4,32,894	4,82,335	

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)									
EPS	21.0	26.3	28.7	35.2	48.9	63.4	67.3	70.3	65.6
Cash EPS	35.5	41.3	44.1	49.4	64.2	81.2	87.8	91.9	87.4
BV/Share	169.0	187.9	212.6	229.0	277.3	336.8	404.8	470.0	530.6
DPS	4.0	4.7	5.0	4.1	4.1	4.3	4.3	4.3	4.3
Payout (%)	21.3	23.5	26.8	16.9	9.0	7.5	7.7	7.1	7.6
Valuation (x)									
P/E	55.1	44.1	40.3	32.9	23.7	18.3	17.2	16.5	17.7
Cash P/E	32.6	28.0	26.2	23.4	18.1	14.3	13.2	12.6	13.2
P/BV	6.9	6.2	5.4	5.1	4.2	3.4	2.9	2.5	2.2
EV/Sales	6.4	5.7	5.0	4.5	3.8	3.2	2.9	2.6	2.4
EV/EBITDA	33.2	26.8	21.2	21.0	14.7	11.4	11.0	10.1	9.6
Dividend Yield (%)	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Return Ratios (%)									
ROIC	10.8	21.9	17.0	18.0	23.1	27.6	20.8	17.2	16.6
RoE	13.1	14.7	14.3	16.0	19.3	20.7	18.2	16.1	13.1
RoCE	8.9	17.4	11.8	12.3	15.9	18.4	14.7	12.1	10.4
Working Capital Ratios									
Fixed Asset Turnover (x)	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.4	1.3
Debtor (Days)	97	100	98	100	106	100	96	103	104
Inventory (Days)	75	75	77	83	75	73	76	76	74
Payable (Days)	32	32	32	38	39	38	37	37	35
Leverage Ratio									
Current Ratio (x)	1.8	1.8	2.1	2.1	2.0	2.1	2.2	2.7	3.4
Net Debt/Equity (x)	0.0	-0.1	-0.2	-0.2	-0.3	-0.3	-0.1	-0.3	-0.6

Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Op. Profit/(Loss) before Tax	23,358	18,857	28,835	30,614	60,485	72,010	76,795	78,578	73,312
Depreciation	11,348	11,631	12,288	11,652	12,502	14,700	17,037	18,044	18,204
Interest/Dividends Recd.	119	90	144	-7	248	-567	152	-901	-1,101
Direct Taxes Paid	-4,841	-7,105	-5,716	-7,437	-10,714	-20,047	-19,993	-20,037	-18,695
(Inc)/Dec in WC	1,837	-7,536	-8,288	-18,407	-7,855	-20,182	-29,989	-17,266	16,460
Other Items	-3,117	13,904	8,440	11,693	4,209	-481	2,426		
CF from Operations	28,704	29,841	35,703	28,108	58,875	45,433	46,428	58,418	88,180
EO Expense	0	0	0	0	0	0	0	0	0
CF from Operations	32,427	30,056	35,703	28,108	58,875	45,433	46,428	58,418	88,180
(inc)/dec in FA	-6,226	-5,725	-12,476	-15,733	-18,784	-26,350	-33,154	-21,588	-8,863
Free Cash Flow	22,478	24,116	23,227	12,375	40,091	19,083	13,274	36,830	79,318
(Pur)/Sale of Investments	-2,282	-214	4,110	-11,201	-23,366	-15,716	25,118	0	0
Others	816	991	-14,181	1,280	1,063	1,724	-42,985		
CF from Investments	-7,692	-4,948	-22,547	-25,654	-41,087	-40,342	-51,021	-21,588	-8,863
Change in net worth	0	4	269	334	368	805	193	0	0
(Inc)/Dec in Debt	-15,182	-19,165	6,094	2,735	-20,397	4,346	23,196	-1,000	-1,000
Other Items	-2,142	-2,082	-2,514	-1,345	-1,853	-2,266	-4,872		
Dividend Paid	-4,002	-3,916	-4,147	-4,146	-4,979	-6,648	-6,662	-4,076	-4,076
CF from Fin. Activity	-21,326	-25,159	-298	-2,422	-26,861	-3,763	11,855	-5,076	-5,076
Inc/Dec of Cash	3,409	-51	12,858	32	-9,073	1,328	7,262	31,754	74,242
Add: Beginning Balance	2,542	2,228	2,053	14,829	14,852	5,779	7,107	14,654	47,207
Closing Balance	5,951	2,177	14,911	14,861	5,779	7,107	14,369	46,408	1,21,449
Bank balance/overdraft	-3,854	-190	0	-9	0	0	61	799	999
Closing Balance	2,228	1,962	14,820	14,852	5,779	7,107	14,654	47,207	1,22,448

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interest pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN.: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.